Johnson & Johnson’s 10-year TB initiative
Active Since: 2018
Contributing to SDGs…
Decade commitment to improving detection of undiagnosed cases of TB, continuing to broaden access to treatment, and accelerating research & development (R&D) to discover next-generation TB treatments
Johnson & JohnsonCompany Profile
To save an estimated 1.8 million lives and prevent 12 million new TB infections over the next decade by improving detection of undiagnosed cases of TB, continuing to broaden treatment access, and accelerating research & development (R&D) to discover next-generation TB treatments.
What are the health needs and challenges?
Tuberculosis (TB) is the world’s deadliest infectious disease, claiming 1.6 million lives every year. Approximately, 95% of these deaths occur in low- and middle-income countries. Growing resistance to the most commonly-used TB medicines is compounding this challenge. In fact, there are more than half a million cases of drug-resistant tuberculosis (DR-TB) every year, and DR-TB is now the leading cause of deaths from antimicrobial resistance (AMR).
Notably, only one in three patients with DR-TB are diagnosed, meaning that there are approximately 400,000 people with DR-TB who aren’t aware they have it. Every person who is not on treatment can infect an additional 15 people over the course of a year, posing a major threat to global health security.
Greater innovation is urgently needed – including innovative approaches to reaching patients today and innovation in the lab to develop shorter, simpler and better-tolerated treatment regimens for tomorrow.
Partnership activities and how they address needs and challenges
At the TB Innovation Summit in September 2018, Johnson & Johnson announced a comprehensive 10-year TB initiative, indicating the company’s long-term commitment to do its part to help the global community achieve its ambitious goal of ending this devastating disease.
Johnson & Johnson has a long history of innovating to develop new TB tools and technologies. Inspired by the legacy of Dr. Paul Janssen, who lost his 4-year-old sister to tubercular meningitis in the 1940s. This tragic event led Dr. Janssen to devote his life to medical research, and ultimately, to found what is now the Janssen Pharmaceutical Companies of Johnson & Johnson. During his lifetime, Dr. Janssen wanted to end TB. Today, the company bearing his name is determined to achieve this mission.
With the goal of saving an estimated 1.8 million lives and preventing 12 million new TB infections in the next decade, Johnson & Johnson is working with partners to improve detection of undiagnosed cases of TB, broaden access to its novel medicine for multidrug-resistant TB (bedaquiline), and accelerate research & development (R&D) to discover next-generation TB treatments.
This comprehensive initiative builds on Johnson & Johnson’s significant investments over two decades in the discovery, development and delivery of bedaquiline. When bedaquiline was conditionally approved by the FDA in 2012, it was the first targeted TB medicine with a novel mechanism of action in more than 40 years. Today, it is approved in 61 countries*, including those with the highest TB burden.
To date, Johnson & Johnson has provided nearly more than 110,000 courses of treatment* to patients in 125 countries*, including through a four-year donation program with United States Agency for International Development (USAID) and JSC Pharmstandard (*figures as of May 2019).
“TB is the worlds number one infectious killer, and TB and MDR-TB cause major devastation for people, communities and entire countries around the world. The good news is TB is both preventable and treatable, and Johnson & Johnson is committed to doing everything we can to create a world free from TB. This new initiative will unleash the power of science and technology to forever change the trajectory of TB.”
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
- 3.3: Communicable Diseases & NTDs
SDG 9: Industry Innovation and Infrastructure
SDG 17: Partnerships for the Goals
Infectious and Parasitic Disease
- Drug-Resistant Infections (AMR)